Related Experiment Videos
Outcome predictors in substance use disorders.
Domenic A Ciraulo1, Joanna Piechniczek-Buczek, E Nalan Iscan
1Division of Psychiatry, Boston University School of Medicine, Doctor's Office Building, 720 Harrison Avenue, Suite 914, Boston, MA 02118, USA. dciraulo@bu.edu
The Psychiatric Clinics of North America
|June 5, 2003
Summary
Predictors of substance abuse treatment response vary but include dependence severity, psychiatric issues, and motivation. Addressing these factors and exploring biologic markers can improve treatment outcomes.
Area of Science:
- Addiction Medicine
- Psychiatry
- Neuroscience
Background:
- Substance abuse treatment response is highly variable.
- Numerous factors influence treatment outcomes, independent of the primary drug or setting.
- Consistent predictors include dependence severity, psychiatric comorbidity, motivation, and social factors.
Purpose of the Study:
- To review identified predictors of substance abuse treatment response.
- To highlight the development of interventions based on these predictors.
- To discuss the role of biologic markers and future research directions.
Main Methods:
- Literature review of factors associated with substance abuse treatment outcomes.
- Analysis of consistently identified predictors across diverse studies.
- Examination of emerging biologic markers and pharmacogenetic approaches.
Main Results:
- Key predictors include severity of dependence, psychiatric comorbidity, motivation, coping skills, and social/economic factors.
- Interventions targeting these factors, such as treating comorbidity and enhancing functioning, improve outcomes.
- Biologic markers like neuroendocrine response and sleep architecture show promise but require further investigation.
Conclusions:
- Understanding and addressing individual patient factors is crucial for effective substance abuse treatment.
- Biologic markers and pharmacogenetics offer potential for personalized therapies.
- Future research should focus on identifying specific predictors for different subgroups and novel treatments.